Ideas

Molecular therapy for Metabolic diseases: A pharmaceutical mixture encompassing 17-β Estradiol (Estradiol-E2) and/or Pyridoxamine(PM) (E2PM) increases the expression of Caveolin-1, stabilizes insulin receptor, promotes insulin sensitivity, incrases vasorelaxation, and decreases the risk of hyperglycemia and TIIDM via up regulation of its target gene.., 4/February/2017, 9.55 am
Molecular therapy for Metabolic diseases: A pharmaceutical mixture encompassing 17-β Estradiol (Estradiol-E2) and/or Pyridoxamine(PM) (E2PM) increases the expression of Caveolin-1, stabilizes insulin receptor, promotes insulin sensitivity, incrases vasorelaxation, and decreases the risk of hyperglycemia and TIIDM via up regulation of its target gene.., 4/February/2017, 9.55 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the Institute for Molecular Systems Biology, ETH Zurich, Zurich, Switzerland shows that “MicroRNAs 103 and 107 regulate insulin sensitivity.” This study was published, in the June 8, 2011 Nature [One of…

read more

Anti-infective Therapy:  Roscovitine, a cyclin-kinase dependent inhibitor, inhibits Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Influenza H1NI1,  respiratory syncytial,  Sindbis, and SFV viruses by increasing the Levels of the Antiviral Proteins IFITM3, & Interferon-stimulated gene 15, 4/February/2018,  9.41 am
Anti-infective Therapy:  Roscovitine, a cyclin-kinase dependent inhibitor, inhibits Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Influenza H1NI1,  respiratory syncytial,  Sindbis, and SFV viruses by increasing the Levels of the Antiviral Proteins IFITM3, & Interferon-stimulated gene 15, 4/February/2018,  9.41 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A study from the Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard Medical School, Charlestown, MA 02129, USA shows that “The IFITM proteins…

read more

Molecular therapy for body weight control, energy homeostasis and TIIDM: A pharmaceutical mixture encompassing Pyridoxamine and Triiodothyronine (T3) (PT3) inhibits DNA methyltransferase 3a (Dnmt3a) expression, increases FGF21 expression, augments insulin sensitivity, increases glucose tolerance, and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 4/February/2018, 9.30 am
Molecular therapy for body weight control, energy homeostasis and TIIDM: A pharmaceutical mixture encompassing Pyridoxamine and Triiodothyronine (T3) (PT3) inhibits DNA methyltransferase 3a (Dnmt3a) expression, increases FGF21 expression, augments insulin sensitivity, increases glucose tolerance, and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 4/February/2018, 9.30 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say  A study from Nutritional Sciences and Toxicology Department, University of California, Berkeley, Berkeley, United States shows that “Dnmt3a is an epigenetic mediator of adipose insulin resistance.”…

read more

Hormonal therapy for Diabetic retinopathy: A pharmaceutical mixture encompassing  Triidothyronine (T3), Epicatechin and Matrine (T3EM)  inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down regulation of its target gene, 3/February/2018, 12.42 am
Hormonal therapy for Diabetic retinopathy: A pharmaceutical mixture encompassing  Triidothyronine (T3), Epicatechin and Matrine (T3EM)  inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down regulation of its target gene, 3/February/2018, 12.42 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the Institute for Vascular Signalling, Centre for Molecular Medicine, Goethe University, Frankfurt am Main, Germany; and German Centre for Cardiovascular Research (DZHK) partner…

read more

Molecular therapy for attenuating pathogenesis-associated with Myocardial infarction: A pharmaceutical mixture encompassing Rosuvastatin, Docosahexaenoic acid and 5 aminolevulinic acid  decreases IRF3, GM-CSF (Granulocyte-macrophage colony-stimulating factor) and GRK2(G protein-coupled receptor kinase) expression, inhibits undue leucocyte activation and invasion, suppresses recruitment of inflammatory cells, inhibits ventricular dilation, and promotes heart repair and survival via up regulation of its target gene, 3/February/2018, 12.29 am
Molecular therapy for attenuating pathogenesis-associated with Myocardial infarction: A pharmaceutical mixture encompassing Rosuvastatin, Docosahexaenoic acid and 5 aminolevulinic acid  decreases IRF3, GM-CSF (Granulocyte-macrophage colony-stimulating factor) and GRK2(G protein-coupled receptor kinase) expression, inhibits undue leucocyte activation and invasion, suppresses recruitment of inflammatory cells, inhibits ventricular dilation, and promotes heart repair and survival via up regulation of its target gene, 3/February/2018, 12.29 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say:  A recent study from Department of Systems Biology, Harvard Medical School, Boston, Massachusetts, USA; and Cardiovascular Research Center, Massachusetts General Hospital and Harvard Medical School, Boston,…

read more

Cardiac rejuvenation therapy: A therapeutic mix encompassing Aspirin and  Hydralazine suppresses tumor suppressor INK4a/p16 expression, and inhibits dilated cardiomyopathy via up regulation of its target gene, 3/February/2018, 12.20 pm
Cardiac rejuvenation therapy: A therapeutic mix encompassing Aspirin and  Hydralazine suppresses tumor suppressor INK4a/p16 expression, and inhibits dilated cardiomyopathy via up regulation of its target gene, 3/February/2018, 12.20 pm 960 720 Dr Boomi's Genom-2-Discovery Center

What we say: Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Cardiac rejuvenation therapy: A therapeutic mix encompassing Aspirin and  Hydralazine suppresses tumor suppressor INK4a/p16 expression, and inhibits dilated cardiomyopathy…

read more
Start Typing